In this article by the Medicine Maker, Asma Patel and John McDermott talk about the complexities of developing modified release formulations.
These formulations allow more control over drug release in the gastrointestinal (GI) tract, providing benefits such as prolonged drug plasma levels, reduced dosing frequency, and targeted delivery. To optimize drug delivery, a “translational pharmaceutics” approach evaluates a “design space” within clinical studies, aligning with ICH Q8 quality-by-design principles.
Continue reading the article on Medicine Maker.